Data gathered: June 23
AI Stock Analysis - TG Therapeutics (TGTX)
Analysis generated March 27, 2025. Powered by Chat GPT.
TG Therapeutics, Inc. (TGTX) is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases. Its current portfolio includes Ublituximab, a monoclonal antibody, and Umbralisib, an oral inhibitor of PI3K delta. The company capitalizes on innovative therapies to target unmet medical needs, especially in contexts such as oncology and autoimmune diseases. Given its research focus and niche operations, TG Therapeutics is positioned to potentially make significant advancements in medical treatments, though it also faces considerable investment risks due to the volatile nature of the biopharmaceutical sector.
Stock Alerts - TG Therapeutics (TGTX)
 |
TG Therapeutics | June 17 Insider Alert: Echelard Yann is selling shares |
|
TG Therapeutics | June 5 Price is up by 7.2% in the last 24h. |
|
TG Therapeutics | May 6 Price is down by -7.4% in the last 24h. |
|
TG Therapeutics | May 5 Price is down by -8.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for TG Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 46 | Sign up | Sign up | Sign up |
| Google Trends | 48 | Sign up | Sign up | Sign up |
| Patents | 7 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 254 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 20,869 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,152 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 20 | Sign up | Sign up | Sign up |
| Linkedin Employees | 430 | Sign up | Sign up | Sign up |
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases.
| Price | $36.56 |
| Target Price | Sign up |
| Volume | 1,580,000 |
| Market Cap | $5.72B |
| Year Range | $23.13 - $45.51 |
| Dividend Yield | 0% |
| PE Ratio | 144.08 |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
 |
TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Holdings Trimmed by Assenagon Asset Management S.A.June 20 - ETF Daily News |
 |
Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics StockJune 17 - Biztoc.com |
 |
Are Options Traders Betting on a Big Move in TG Therapeutics Stock?June 15 - Yahoo |
|
Cantor Fitzgerald Forecasts TG Therapeutics FY2026 EarningsJune 11 - ETF Daily News |
Transcript : TG Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10June 9 - Finnhub |
|
|
GAMMA Investing LLC Raises Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)June 9 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 121M | 16M | 105M | 5.1M | 8.6M | 0.030 |
| Q4 '24 | 108M | 15M | 93M | 23M | 32M | 0.150 |
| Q3 '24 | 84M | 9.3M | 75M | 3.9M | 15M | 0.020 |
| Q2 '24 | 73M | 8.4M | 65M | 6.9M | 11M | 0.040 |
| Q1 '24 | 63M | 5.5M | 58M | -11M | -8.3M | -0.070 |
Insider Transactions View All
| Echelard Yann filed to sell 228,816 shares at $36.9. June 16 '25 |
| Power Sean A filed to sell 660,611 shares at $28.5. January 7 '25 |
| Power Sean A filed to sell 670,632 shares at $30.3. January 7 '25 |
| Lonial Sagar filed to sell 100,195 shares at $30.4. November 12 '24 |
| Charney Laurence N filed to sell 212,479 shares at $30.2. November 12 '24 |
Similar companies
Read more about TG Therapeutics (TGTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of TG Therapeutics?
The Market Cap of TG Therapeutics is $5.72B.
What is TG Therapeutics' PE Ratio?
As of today, TG Therapeutics' PE (Price to Earnings) ratio is 144.08.
What is the current stock price of TG Therapeutics?
Currently, the price of one share of TG Therapeutics stock is $36.56.
How can I analyze the TGTX stock price chart for investment decisions?
The TGTX stock price chart above provides a comprehensive visual representation of TG Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling TG Therapeutics shares. Our platform offers an up-to-date TGTX stock price chart, along with technical data analysis and alternative data insights.
Does TGTX offer dividends to its shareholders?
As of our latest update, TG Therapeutics (TGTX) does not offer dividends to its shareholders. Investors interested in TG Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of TG Therapeutics?
Some of the similar stocks of TG Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.